We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$742M
AUM Growth
-$165M
Cap. Flow
-$34.2M
Cap. Flow %
-4.61%
Top 10 Hldgs %
45.48%
Holding
92
New
8
Increased
13
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
KA
Kineta, Inc. Common Stock
KA
+$16.9M
2
BPMC
Blueprint Medicines
BPMC
+$16.4M
3
TBPH icon
Theravance Biopharma
TBPH
+$9.51M
4
NVRO
NEVRO CORP.
NVRO
+$9.42M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$7.84M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$23.4M
2
MGNX icon
MacroGenics
MGNX
+$21.2M
3
CLLS
Cellectis
CLLS
+$12M
4
ADXS
Advaxis Inc
ADXS
+$9.85M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLRB icon
76
Cellectar Biosciences
CLRB
$22.3M
$65K 0.01%
18
– –
CLRBW
77
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$10K ﹤0.01%
52,999
– –
ADAP
78
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-25,307
Closed -$178K
ALNY icon
79
Alnylam Pharmaceuticals
ALNY
$32.3B
– –
-126,120
Closed -$8.55M
ATRA icon
80
Atara Biotherapeutics
ATRA
$99.1M
– –
-7,458
Closed -$3.99M
CLLS
81
Cellectis
CLLS
$140M
– –
-498,117
Closed -$12M
EBS icon
82
Emergent Biosolutions
EBS
$348M
– –
-250,000
Closed -$7.88M
FOLD
83
DELISTED
Amicus Therapeutics
FOLD
– –
-151,838
Closed -$1.12M
IOVA icon
84
Iovance Biotherapeutics
IOVA
$4.48B
– –
-505,941
Closed -$4.16M
MGNX icon
85
MacroGenics
MGNX
$260M
– –
-707,978
Closed -$21.2M
CYAD
86
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
– –
-75,920
Closed -$1.79M
CLVS
87
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-650,000
Closed -$23.4M
ADXS
88
DELISTED
Advaxis Inc
ADXS
– –
-61,394
Closed -$9.85M
ACHN
89
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,006,128
Closed -$8.15M
PVCT.WS
90
DELISTED
PROVECTUS BIOPHARMACEUTICALS INC WTS (DE)
PVCT.WS
– –
-2,200,000
Closed -$114K
PVCT
91
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
– –
-2,226,961
Closed -$221K
GNVC
92
DELISTED
GenVec, Inc.
GNVC
– –
-101,569
Closed -$468K
1 2 3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Cormorant Asset Management held 92 positions worth $742M, down 18% from $907M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $34.2M in Q4 2016, closing 15 positions and reducing 17 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Synergy Pharmaceuticals, Inc Common Stock worth $9.13M.

  • Cormorant Asset Management's largest Q4 2016 buy was Synergy Pharmaceuticals, Inc Common Stock: 1,500,000 shares worth $9.13M.
  • Cormorant Asset Management added most to Kineta, Inc. Common Stock in Q4 2016, an estimated $16.9M increase.
  • Cormorant Asset Management's biggest Q4 2016 reduction was Omeros, cutting an estimated $7.35M.
  • Cormorant Asset Management fully exited Clovis Oncology, Inc. in Q4 2016, selling an estimated $23.4M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $742M portfolio in Q4 2016.
  • Cormorant Asset Management opened 8 new positions and closed 15 in Q4 2016.
  • Cormorant Asset Management's portfolio value fell 18% quarter-over-quarter to $742M.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.